Study: PET useful for distinguishing forms of dementia

04/22/2013 | MolecularImaging.net

PET imaging with 11C-dihydotetrabenazine to determine striatal dopamine terminal integrity and with 11C-Pittsburgh compound B to measure cerebral amyloid accumulation can help classify mild cognitive impairment as it develops into Alzheimer's disease, frontotemporal dementia or Lewy body dementia, according to a study published in The Journal of Nuclear Medicine. The dual-target PET technique identified 18 patients with Alzheimer's pathology, seven with FTD characteristics and two with signs of LBD, the study said. Most went on to develop dementia. Having a model for distinguishing between types of MCI could enhance future clinical trials, researchers said.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL